Trial reportBJU international2025
Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.
Trial report in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03350529 (Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the safety and efficacy of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). PATIENTS AND
methodsThis prospective, single-centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate-specific antigen (PSA) levels, and validated questionnaires at baseline and 3-month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien-Dindo classification.
resultsThe median patient age at treatment was 67 years. During the 12-month post-TULSA follow-up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s (P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s (P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 (P < 0.001), and IPSS quality of life score improved from 4 to 1 (P < 0.001). The 26-item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 (P < 0.001), and urinary incontinence scores improved from 86 to 100 (P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow-up.
conclusionsTransurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long-term outcomes and validation in larger cohorts remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.